Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pan-serotype dengue vaccine
- Development stage
- Preclinical
- Lead developer
- MindWalk Holdings
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intramuscular, Parenteral
01
Overview
The pan-serotype dengue vaccine is a preclinical-stage therapeutic and prophylactic candidate developed by MindWalk Holdings (formerly ImmunoPrecise Antibodies). The program is designed to provide broad protection against all four serotypes of the dengue virus (DENV-1, DENV-2, DENV-3, and DENV-4) by targeting a highly conserved epitope on the envelope protein domain III (EDIII). This approach aims to elicit cross-reactive neutralizing antibodies, potentially overcoming the challenges of serotype-specific immunity and the risk of antibody-dependent enhancement (ADE), a common complication in dengue vaccine development. The program utilizes the HYFT computational platform for epitope prediction and has achieved in vivo proof-of-concept, currently advancing toward manufacturing stages.
- Other names
- Universal Dengue mAb/VaccineUniversal Dengue VaccineUniversal Dengue Monoclonal Antibody
02
Targets
EDIII (Dengue virus envelope glycoprotein domain III)DENV (Flavivirus antigens and proteins)
Beyond the preview
Go deeper on pan-serotype dengue vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pan-serotype dengue vaccine.